Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Abràs, Alba; Gállego, Montserrat; Llovet, Teresa; Tebar, Sílvia; Herrero, Mercedes; Berenguer, Pere; Ballart, Cristina; Marti, Carmen Gonzalez; Muñoz, Carmen

doi:10.1128/jcm.00142-16

Cited by 58 publications

(64 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As many as 284/307 (92.5%) confirmed chronic Chagas disease patients [29], this strategy could have saved 39 013 tests. Other authors from a different Spanish region proposed a similar algorithm with a slightly higher S/CO, but fewer reactive samples [18]. A multicenter study would be useful to unify these results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease

Pérez‐Ayala

Fradejas

Rebollo

et al. 2018

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Other authors from a different Spanish region proposed a similar algorithm with a slightly higher S/CO, but fewer reactive samples . A multicenter study would be useful to unify these results.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease

Pérez‐Ayala

Fradejas

Rebollo

et al. 2018

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

“…New generation tests displaying potentially improved accuracy such as the Chemoluminescent Microparticle ImmunoAssay (CMIA) and its improved version, Architect Chagas (both from Abbott Laboratories, Wiesbaden, Germany) (Abras et al, 2016; Praast et al, 2011), or the Multi-cruzi test (InfYnity Biomarkers, Lyon, France) (Granjon et al, 2016) have been recently developed. Confirming the above mentioned trend, both use a large panel of T. cruzi antigens belonging to the 'parental repertoire' -those discovered in the 80's-, which in the case of the Multi-cruzi test is supplemented with TSSA (Trypomastigote Small Surface Antigen (Di Noia et al, 2002)).…”

Section: Diagnostic Applications For Chagas D Isease: Present Knowledgementioning

confidence: 99%

“…Confirming the above mentioned trend, both use a large panel of T. cruzi antigens belonging to the 'parental repertoire' -those discovered in the 80's-, which in the case of the Multi-cruzi test is supplemented with TSSA (Trypomastigote Small Surface Antigen (Di Noia et al, 2002)). Despite the virtual lack of antigen innovation, these tests incorporate a large degree of automation and highly sensitive detection systems (Abras et al, 2016) or major technical improvements, such as a multiplexed printing method inside ELISA microplates (Granjon et al, 2016). …”

Section: Diagnostic Applications For Chagas D Isease: Present Knowledgementioning

confidence: 99%

Chagas Disease Diagnostic Applications

Balouz

Agüero

Buscaglia

2017

Advances in Parasitology

View full text Add to dashboard Cite

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long and debilitating illness of major significance throughout Latin America, and an emergent threat to global public health. Being a neglected disease, the vast majority of Chagasic patients have limited access to proper diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine development. In this context, identification of novel biomarkers able to transcend the current limits of diagnostic methods surfaces as a main priority in Chagas disease applied research. The expectation is that these novel biomarkers will provide reliable, reproducible and accurate results irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-associated features of Chagasic populations. In addition, they should be able to address other still unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid assessment of treatment efficiency or failure, indication/prediction of disease progression and direct parasite typification in clinical samples. The lack of access of poor and neglected populations to essential diagnostics also stress the necessity of developing new methods operational in Point-of-Care (PoC) settings. In summary, emergent diagnostic tests integrating these novel and tailored tools should provide a significant impact on the effectiveness of current intervention schemes and on the clinical management of Chagasic patients. In this chapter, we discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, as well as the opportunity provided by recent advances in high-throughput methods for biomarker discovery.

show abstract

“…Second, computational discovery using epitope repertoires from other infectious diseases enabled optimization of motif combinations to minimize cross-reactivity in non-Chagas sera. We discovered the motif [ADP]GGFG to be enriched in the epitope repertoires from specimens seropositive for either T. cruzi or Leishmania sp., (an organism known to generate false positive Chagas test results 23 ). Identification and removal of the shared epitope did not adversely affect diagnostic panel performance.…”

Section: Discussionmentioning

confidence: 99%

Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology

Kamath

Reifert

Johnston

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The detection of pathogen-specific antibodies remains a cornerstone of clinical diagnostics. Yet, many test exhibit undesirable performance or are completely lacking. Given this, we developed serum epitope repertoire analysis (SERA), a method to rapidly discover conserved, pathogen-specific antigens and their epitopes, and applied it to develop an assay for Chagas disease caused by the protozoan parasite Trypanosoma cruzi. Antibody binding peptide motifs were identified from 28 Chagas repertoires using a bacterial display random 12-mer peptide library and next-generation sequencing (NGS). Thirty-three motifs were selected and mapped to candidate Chagas antigens. In a blinded validation set (n = 72), 30/30 Chagas were positive, 30/30 non-Chagas were negative, and 1/12 Leishmania sp. was positive. After unblinding, a Leishmania cross-reactive epitope was identified and removed from the panel. The Chagas assay exhibited 100% sensitivity (30/30) and specificity (90/90) in a second blinded validation set including individuals with other parasitic infections. Amongst additional epitope repertoires with unknown Chagas serostatus, assay specificity was 99.8% (998/1000). Thus, the Chagas assay achieved a combined sensitivity and specificity equivalent or superior to diagnostic algorithms that rely on three separate tests to achieve high specificity. NGS-based serology via SERA provides an effective approach to discover antigenic epitopes and develop high performance multiplex serological assays.

show abstract

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Cited by 58 publications

References 61 publications

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease

Chagas Disease Diagnostic Applications

Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology

Contact Info

Product

Resources

About

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Cited by 58 publications

References 61 publications

Usefulness of the ARCHITECT Chagas® assay as a single test for the diagnosis of chronic Chagas disease

Usefulness of the ARCHITECT Chagas® assay as a single test for the diagnosis of chronic Chagas disease

Chagas Disease Diagnostic Applications

Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology

Contact Info

Product

Resources

About

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease

Usefulness of the ARCHITECT Chagas^® assay as a single test for the diagnosis of chronic Chagas disease